10-Q: Roivant Sciences Reports Q3 Loss Amid R&D Surge, Pipeline Advances

Roivant Sciences reported a significant net loss for Q3 2025, driven by increased R&D and G&A expenses, despite a strong cash position and ongoing clinical pipeline progress.

Summary

• Roivant Sciences Ltd. (RSL) reported a net loss of $313.7 million for the three months ended December 31, 2025, compared to a net income of $118.1 million for the same period in 2024.
• For the nine months ended December 31, 2025, the net loss was $753.7 million, a substantial increase from a net loss of $104.4 million in the prior year period.
• Revenue decreased by $7.0 million to $2.0 million for the three months ended December 31, 2025, and by $15.7 million to $5.7 million for the nine months ended December 31, 2025, primarily due to license agreements at Genevant.
• Research and development (R&D) expenses increased by $23.8 million to $165.4 million for the three months, and by $77.7 million to $482.9 million for the nine months, reflecting program progression and share-based compensation.
• General and administrative (G&A) expenses rose by $33.5 million to $175.1 million for the three months, and by $7.9 million to $452.2 million for the nine months, partly due to an impairment loss and share-based compensation.
• The company held approximately $4.5 billion in cash, cash equivalents, and marketable securities as of December 31, 2025, down from $4.9 billion as of March 31, 2025.
• Immunovant, a subsidiary, completed an underwritten offering in December 2025, raising approximately $543.6 million, increasing RSL's ownership to 56%.
• Priovant announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis and submitted a New Drug Application (NDA) for brepocitinib in dermatomyositis.
• Genevant received a favorable summary judgment decision in the U.S. Moderna case, affirming its view on Section 1498, with a jury trial scheduled for March 2026.
• The Earn-Out Shares liability, totaling $57.7 million, vested during the quarter ended December 31, 2025, and was reclassified to additional paid-in capital.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company maintains a strong cash position and shows promising clinical progress, the significant increase in net losses and declining revenue from continuing operations raise concerns about the burn rate and path to profitability. The ongoing legal battles and regulatory uncertainties add to the risk profile.

Positives

• Strong liquidity position with approximately $4.5 billion in cash, cash equivalents, and marketable securities as of December 31, 2025, providing a cash runway into profitability.
• Priovant announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, showing significant improvement in disease activity (21.6 p<0.0001) and a consistent safety profile.
• A New Drug Application (NDA) for brepocitinib in dermatomyositis was submitted to the FDA, indicating progress towards potential commercialization.
• Immunovant's potentially registrational trial for IMVT-1402 in difficult-to-treat rheumatoid arthritis is fully enrolled, with topline data expected in 2H 2026.
• Pulmovant's Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease is fully enrolled, with topline data expected in 2H 2026.
• Genevant received a favorable summary judgment decision in the U.S. Moderna case, affirming that the significant majority of liability belongs in the current case against Moderna.
• The vesting of Earn-Out Shares, previously a liability, resulted in a reclassification of $57.7 million to additional paid-in capital, removing a contingent liability.

Negatives

• Net loss significantly widened to $313.7 million for the three months ended December 31, 2025, from a net income of $118.1 million in the prior year period.
• Net loss for the nine months ended December 31, 2025, increased to $753.7 million, compared to $104.4 million in the prior year period.
• Revenue decreased by $7.0 million (77.8%) for the three months and $15.7 million (73.3%) for the nine months ended December 31, 2025, primarily due to lower license agreement income.
• Research and development expenses increased by $23.8 million (16.8%) for the three months and $77.7 million (19.2%) for the nine months, indicating higher burn rate for pipeline development.
• General and administrative expenses increased by $33.5 million (23.7%) for the three months and $7.9 million (1.8%) for the nine months, partly due to an impairment loss and increased share-based compensation.
• Interest income decreased by $18.6 million for the three months and $66.8 million for the nine months, primarily due to lower cash balances and interest rates.
• The company's accumulated deficit grew to $695.0 million as of December 31, 2025, from a retained earnings of $116.1 million as of March 31, 2025, reflecting ongoing losses.
• The company no longer has a commercial-stage product following the Dermavant Transaction in October 2024, meaning no near-term product revenues are expected.

Risks

• Relatively limited operating history and inherent uncertainties in biopharmaceutical product development and commercialization make it difficult to assess future prospects.
• May not be successful in efforts to acquire or in-license new product candidates, or newly acquired candidates may not perform as expected in clinical trials or achieve marketing approvals.
• Immunovant relies on the HanAll Agreement for IMVT-1402 and batoclimab intellectual property; termination or loss of significant rights would adversely affect development and commercialization.
• Likely to incur significant operating losses for the foreseeable future and may never achieve sustained profitability.
• Risks associated with the allocation of capital and personnel across businesses, potentially missing viable opportunities.
• Risks associated with the Vant structure, including increased costs, key employee risks, and limited operational control in non-wholly owned Vants.
• Risks associated with potential future milestone and royalty payments owed in connection with product candidates, which could be substantial and due before products generate sufficient funds.
• Risks associated with acquisitions, divestitures, and other strategic transactions, including failure to realize expected benefits or integration difficulties.
• Risks associated with the use of cash, cash equivalents, and marketable securities, including market volatility and inability to find suitable strategic transactions.
• Exposure to risks related to significant holdings of cash, cash equivalents, and marketable securities, including market and economic conditions, political risk, and interest rate fluctuations.
• While no near-term need for additional capital, future capital may be required, and failure to obtain it could delay or terminate development programs.
• Business strategy and future growth rely on assumptions that may not be realized, impacting market acceptance and size.
• Drug discovery efforts may not be successful in identifying new product candidates or advancing them through clinical trials.
• Unfavorable, uncertain, and rapidly changing global and regional economic, political, and public health conditions could adversely affect business.
• Disruption in Asia (manufacturing, research, clinical trials) due to trade wars or political unrest could materially adversely affect business.
• Inadequate or uncertain funding levels for the FDA, USPTO, SEC, or other government agencies could hinder, delay, or suspend operations.
• Clinical trials and preclinical studies are expensive, time-consuming, difficult to design, and involve uncertain outcomes, potentially leading to substantial delays or inability to complete.
• Difficulties enrolling and retaining patients in clinical trials could delay or adversely affect clinical development activities.
• Results of preclinical studies and clinical trials may not support proposed claims or regulatory approvals, and earlier results may not be predictive of future trials.
• Interim, preliminary, or topline data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Changes in methods of product manufacturing or formulation may result in additional costs or delays.
• Obtaining approval of a new drug is extensive, lengthy, expensive, and uncertain; FDA or other authorities may delay, limit, or deny approval.
• Clinical trials may fail to demonstrate substantial evidence of safety and efficacy, preventing, delaying, or limiting regulatory approval and commercialization.
• Product candidates may cause undesirable side effects, halting development, delaying approval, limiting label scope, or resulting in negative consequences.
• Regulatory approval processes are lengthy and unpredictable; approval in one country does not guarantee approval in others.
• Reliance on third parties to conduct, supervise, and monitor clinical trials, with unsatisfactory performance harming the business.
• No own manufacturing capabilities; reliance on third parties for clinical and commercial supplies, posing risks of delays or quality issues.
• High dependence on key personnel; failure to attract, motivate, and retain qualified personnel could hinder business strategy.
• Use of artificial intelligence (AI) could expose the company to liability or adversely affect its business.
• Inability to obtain and maintain patent and other intellectual property protection, or insufficient scope of protection, could impair competitive effectiveness.
• If performance does not meet market expectations, the price of securities may decline.
• Increased costs and management time devoted to compliance as a public company.
• Failure to maintain proper and effective internal control over financial reporting could impair accurate financial statements and reduce investor confidence.
• Anti-takeover provisions in organizational documents and Bermuda law could delay or prevent a change in control.
• Largest shareholders own a significant percentage of common shares and can exert significant control.
• Future sales and issuances of equity securities will result in additional dilution.
• Future sales, or perception of future sales, of common shares could cause market price to decline.
• Exposure to business, legal, regulatory, political, operational, financial, and economic risks associated with conducting business globally.
• Significant competition in an environment of rapid technological and scientific change, with competitors potentially achieving approvals faster or developing superior therapies.
• Litigation and investigation risks, including product liability claims and intellectual property disputes (e.g., Moderna, Pfizer actions), could adversely affect business.
• May not hold a controlling stake in certain Vant affiliates, limiting ability to direct business or product development.
• Internal computer and IT systems, or those of third parties, may fail or suffer cyberattacks, compromising data and exposing to liability.
• Subject to complex and evolving U.S. and foreign laws and regulations relating to privacy and data protection, potentially leading to claims or penalties.
• Employees, consultants, or contractors may wrongfully use or disclose confidential information of former employers or third parties.
• Claims challenging inventorship or ownership of patents and other intellectual property.
• Changes in U.S. patent law or other countries' patent laws could diminish patent value.
• Validity, scope, and enforceability of patents covering product candidates can be challenged by third parties.
• Inability to protect intellectual property rights throughout the world, especially in countries with weaker IP laws.
• Inability to protect the confidentiality of trade secrets, harming business and competitive position.
• Use of AI may introduce intellectual property risks, particularly regarding inventorship and ownership of AI-generated inventions.

Future Outlook

Roivant Sciences expects to continue incurring significant operating losses for the foreseeable future as it advances product candidates through development and clinical trials, and seeks regulatory approval. The company anticipates increased R&D expenses as it funds preclinical studies, clinical trials, manufacturing, and drug discovery efforts. G&A expenses are also expected to rise to support potential commercialization and new personnel. The company plans to in-license multiple potentially category-leading drugs per year. Key upcoming catalysts include topline data from Phase 3 trials for batoclimab in thyroid eye disease (1H 2026), Phase 2 trial for mosliciguat in pulmonary hypertension (2H 2026), Phase 3 trials for brepocitinib in non-infectious uveitis (2H 2026), and Phase 2/3 trials for IMVT-1402 in various indications (2H 2026, 2027, 2028). The jury trial in the U.S. Moderna case is scheduled for March 2026, with first major hearings in ex-U.S. Moderna cases in 1H 2026. The company believes its existing cash, cash equivalents, and marketable securities of $4.5 billion will be sufficient to fund operating expenses and capital expenditures for the foreseeable future, extending its cash runway into profitability.

Management Comments

• Management expects to incur additional losses in the future to fund its operations and conduct product research and development and may require additional capital to fully implement its business plan.
• Management expects there will be an adverse effect on the FDA's ability to efficiently carry out its functions, including conducting inspections and timely reviewing drug and biologic product applications, and a potential impact on how it interprets and enforces its authorities, due to recent workforce reductions and leadership changes.
• Management does not expect that our disclosure controls and procedures, or our internal controls, will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Industry Context

StockSavvy.ai notes that Roivant Sciences operates within the highly competitive and capital-intensive biopharmaceutical and healthcare technology sectors. The company's 'Vant' structure, designed to accelerate drug development, is a unique approach in an industry often characterized by large, bureaucratic R&D pipelines. The significant cash reserves provide a buffer against the inherent risks of drug development, particularly as the company has no commercial-stage products following the Dermavant divestiture. The ongoing legal battles with Moderna and Pfizer highlight the intense intellectual property landscape in novel drug delivery technologies (LNP platform). The increasing R&D spend is consistent with a clinical-stage company pushing multiple candidates through pivotal trials, a common trend for firms aiming for market leadership in specific therapeutic areas like autoimmune diseases and pulmonary hypertension. Regulatory changes, particularly those impacting drug pricing and FDA operations under the Trump administration, introduce significant uncertainty for all players in the U.S. pharmaceutical market.

Comparison to Industry Standards

• Roivant's cash position of $4.5 billion is substantial for a clinical-stage biopharmaceutical company, providing a longer runway compared to many smaller biotech firms that frequently face capital constraints.
• The increase in R&D expenses by 19.2% for the nine months ended December 31, 2025, is typical for a company with multiple product candidates advancing into later-stage clinical trials, such as Immunovant's IMVT-1402 and Priovant's brepocitinib, aligning with industry benchmarks for companies in pivotal development phases.
• The net loss of $753.7 million for the nine months is significant, but not uncommon for biopharmaceutical companies heavily investing in R&D without commercial products, similar to early-stage Moderna or BioNTech before their vaccine commercialization, or other clinical-stage companies like Alnylam Pharmaceuticals in its pre-commercialization phase.
• The positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (21.6 p<0.0001 improvement in CSAMI-A) demonstrate strong efficacy, comparable to or exceeding initial data from other successful autoimmune drug developments, such as Dupixent (dupilumab) in atopic dermatitis or Humira (adalimumab) in various inflammatory conditions, at similar stages of development.
• The legal disputes with Moderna and Pfizer regarding LNP technology are indicative of the high-stakes intellectual property battles seen in the biotech industry, particularly for foundational technologies, akin to past patent disputes involving CRISPR gene editing technology or antibody engineering platforms.

Management Changes

Corporate Governance

Legal Proceedings

• Roivant's subsidiary GSG and affiliate Arbutus filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna and an affiliate in February 2022, seeking damages for infringement of certain patents related to the manufacture and sale of MRNA-1273 (Moderna's COVID-19 vaccine).
• On February 2, 2026, the court ruled substantially in GSG's and Arbutus' favor on the applicability of 28 U.S.C. § 1498(a) in the Moderna Action, with a jury trial scheduled for March 2026.
• GSG and Arbutus filed a lawsuit in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech in April 2023, seeking damages for infringement of patents in the manufacture and sale of COMIRNATY.
• In September 2025, the court issued a claim construction ruling in the Pfizer Action, which GSG generally considers favorable.
• In March 2025, GSG and Arbutus filed five international lawsuits against Moderna in Canada, Japan, Switzerland, and the Unified Patent Court (UPC), targeting alleged infringing activity in 30 countries.
• A European patent (EP2279254) licensed by Genevant from Arbutus was revoked by the Board of Appeal of the EPO in January 2026, which is likely to affect related cases in Switzerland and the UPC. Arbutus plans to appeal.
• A second European patent (EP4241767 B1) licensed by Genevant from Arbutus is subject to an opposition proceeding brought by Moderna at the EPO in 2025.

Related Party Transactions

• Roivant Sciences Ltd. holds an investment in Arbutus Biopharma Corporation, representing approximately 20% of issued and outstanding shares, and recognizes unrealized gains/losses on this investment.
• Roivant Sciences Ltd. holds an investment in Class A units of Datavant, representing approximately 9% of outstanding Class A units, and recognizes unrealized gains/losses on this investment.
• In December 2025, Roivant Sciences Ltd. purchased 16,666,666 shares of Immunovant, Inc. common stock in an underwritten offering, increasing its ownership interest to approximately 56%.
• In November 2025, the company offered certain holders of vested equity of its subsidiary, Priovant Holdings, Inc., the opportunity to exchange a portion of their vested equity for RSL common shares (the Exchange Offer).
• In April 2024, the company repurchased all 71,251,083 common shares held by Sumitomo Pharma Co., Ltd. for approximately $648.4 million.

Stakeholder Impact

• Shareholders: Experience significant dilution from ongoing net losses and potential future equity issuances, but benefit from a strong cash position and potential upside from pipeline successes and intellectual property litigation outcomes. Share repurchase programs aim to return capital.
• Employees: Benefit from equity incentive plans and cash bonus programs, but face risks associated with management transitions and potential workforce reductions in certain Vants or functions.
• Customers (future): Potential for new therapeutic options from Roivant's pipeline, particularly in autoimmune diseases and pulmonary hypertension, if product candidates achieve regulatory approval.
• Suppliers/CROs/CMOs: Continued reliance on third-party service providers for R&D and manufacturing, indicating ongoing business opportunities, but also risks of supply chain disruptions or non-compliance.
• Creditors: The company's substantial cash reserves provide a strong liquidity position, reducing immediate credit risk, but long-term profitability challenges remain a consideration.

Next Steps

• Ongoing new mid/late-stage in-licensing announcements for pipeline growth.
• Jury trial in U.S. Moderna case scheduled for March 2026.
• First major hearings in ex-U.S. Moderna cases expected in 1H 2026.
• Topline data from both Phase 3 trials for batoclimab in thyroid eye disease expected in 1H 2026.
• Topline data from Phase 2 trial for mosliciguat in pulmonary hypertension associated with interstitial lung disease expected in 2H 2026.
• Topline data from Phase 3 trials for brepocitinib in non-infectious uveitis expected in 2H 2026.
• Topline data from Phase 2 trial for IMVT-1402 in cutaneous lupus erythematosus expected in 2H 2026.
• Topline data from potentially registrational trial for IMVT-1402 in ACPA+ difficult-to-treat rheumatoid arthritis expected in 2H 2026.
• Topline data from potentially registrational trials for IMVT-1402 in Graves disease expected in 2027.
• Topline data from potentially registrational trial for IMVT-1402 in myasthenia gravis expected in 2027.
• Topline data from potentially registrational trial for IMVT-1402 in chronic inflammatory demyelinating polyneuropathy expected in 2028.
• Topline data from potentially registrational trial for IMVT-1402 in Sjogren's disease expected in 2028.
• Immunovant to assess the impact of internal reorganization and intellectual property transfer on income tax expense and foreign net operating losses for the year ending March 31, 2026.
• Frank Torti's trading plan for potential sale of up to 3,000,000 common shares between February 19, 2026, and June 30, 2026.

Key Dates

Recommendation

Roivant Sciences presents a mixed financial picture with substantial net losses but a robust cash position and a promising, albeit high-risk, clinical pipeline. The positive Phase 2 results for brepocitinib and the favorable summary judgment in the Moderna litigation are significant catalysts. However, the increasing burn rate, declining revenue, and inherent uncertainties of biopharmaceutical development, coupled with ongoing legal and regulatory risks, warrant a cautious approach. The stock is a 'hold' for investors with a high-risk tolerance who believe in the long-term potential of the Vant model and pipeline, but who should monitor upcoming clinical data readouts and litigation outcomes closely.

Keywords

Biopharmaceutical, Drug Development, Clinical Trials, Autoimmune Diseases, FcRn Inhibitors, TYK2/JAK1 Inhibitors, Pulmonary Hypertension, Genevant, Immunovant, Priovant, Mosliciguat, Brepocitinib, IMVT-1402, LNP Technology, SEC Filing, Biotech, Healthcare Technology, Pharmaceutical, R&D, Net Loss, Cash Position, Intellectual Property, Regulatory Approval, Orphan Drug, Fast Track Designation, Moderna Litigation, Pfizer Litigation, AI in Drug Discovery